Related Experiment Video

Updated: Feb 20, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

992

The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I

Xiu-Qiong Fu1, Ji-Yao Chou1, Ting Li1

  • 1Center for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.

Experimental Dermatology
|October 28, 2017
PubMed

Insights

Atractylenolide I exhibits anti-melanoma properties by reducing cancer cell viability and migration. It functions by inhibiting the JAK2/STAT3 signaling pathway, a key factor in melanoma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Melanoma is an aggressive skin cancer with limited treatment options.
  • The Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway is frequently dysregulated in melanoma, promoting cell survival and proliferation.

Discussion:

  • Atractylenolide I demonstrated significant anti-melanoma effects, including decreased cell viability, induced apoptosis, and inhibited cell migration in human melanoma cells.
  • The compound downregulated key proteins in the JAK2/STAT3 pathway, phospho-JAK2 and phospho-STAT3.
  • This inhibition led to reduced mRNA levels of STAT3-targeted genes crucial for melanoma progression, such as Bcl-xL, MMP-2, and MMP-9.

Key Insights:

  • Atractylenolide I effectively targets melanoma cells by disrupting the JAK2/STAT3 signaling cascade.
  • The anti-melanoma efficacy of atractylenolide I is directly linked to its ability to inhibit JAK2/STAT3 pathway activation.
  • STAT3-overactivated cells showed reduced sensitivity to atractylenolide I, further supporting the pathway's role.

Outlook:

  • Atractylenolide I represents a potential therapeutic candidate for melanoma treatment.
  • Further research into the precise molecular interactions and in vivo efficacy is warranted.
  • Targeting the JAK2/STAT3 pathway with natural compounds like atractylenolide I offers a promising strategy in melanoma therapy.
Keywords:
Cytotoxicityapoptosismetastasismolecular pathwaystargeted therapy

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K